Prime Medicine

Prime Medicine, Inc.
Company type	Public
Traded as	Nasdaq: PRME ;
ISIN	US74168J1016
Industry	Biotechnology
Founded	2021;4 years ago
Founders	David R. Liu ; Andrew Anzalone;
Headquarters	Cambridge, Massachusetts, U.S.
Key people	Allan Reine (CEO); David R. Liu (Co-founder and Scientific Advisory Board member);
Website	primemedicine.com

Last updated December 30, 2025

Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.^[1]

Partnerships

In September 2024, Prime Medicine announced a partnership with Bristol Myers Squibb to develop optimized prime editing reagents for ex vivo T cell therapies. Prime Medicine received $110 million upfront and is eligible for up to $3.5 billion in milestone payments.^[2]

References

This article about a corporation or company specializing in health technology is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "World first: ultra-powerful CRISPR treatment trialled in a person". Nature.

[2] "BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipeline".

[1]

[2]

Prime Medicine

Contents

Partnerships

See also

References